KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.

Josephine Bourner, Michel Vaillant, Alex Paddy Abdel Salam, Marie Jaspard, Camille Fritzell, Shevin T Jacob, Tom E Fletcher, Michael Ramharter, Nnennaya Ajayi, Sylvanus Okogbenin, Cyril Erameh, Donald Grant, Robert Samuels, Oladele Oluwafemi Ayodeji, Armand Sprecher, Bronner P Gonçalves, Tansy Edwards, Piero Olliaro, WALC Work Package 2 Working Group

Emerg Infect Dis 31(2) 9-16

PMID39983682
PMCIDPMC11845141
DOI10.3201/eid3102.240251
发表日期2025-02-21
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas with endemic transmission and epidemic potential, there is an urgent need to reassess ribavirin and investigate other potential therapeutic candidates; however, a robust clinical trial method adapted to Lassa fever epidemiology has not yet been established. We propose an adaptive phase II/III multicenter randomized controlled platform trial that uses a superiority framework with an equal allocation ratio and accounts for challenges selecting the primary end point and estimating the target sample size by using an interim analysis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。